Navigation Links
Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
Date:3/11/2008

rms of heart disease."

About Corgentin

Cardium's Corgentin (Ad5IGF-I) preclinical product candidate is a next-generation DNA-based therapeutic using the insulin-like growth factor-I gene carried by an adenovector that is being developed as a potential one-time treatment to promote the preservation and restoration of heart tissue and cardiac function following a heart attack (acute myocardial infarction). Cardium believes that Corgentin, which effectively enables prolonged IGF-I expression within the heart muscle, offers the potential to prevent further damage to heart muscle and improve cardiac healing following a heart attack. The inherent biological properties of IGF-I, which include inhibition of cardiomyocyte apoptosis, adaptive cardiomyocyte hypertrophy, recruitment of cardiac progenitor cells, as well as the induction of angiogenesis and enhancement of cardiac function, combined with Cardium's delivery approach to yield sustained localized expression, provide the rationale for the development of a therapy directed at myocardial repair and restoration. This combination of positive biological attributes and effective delivery supports the potential of Corgentin to improve functional recovery and prevent ventricular dysfunction and the associated progression to congestive heart failure following myocardial infarction and reperfusion.

According to the American Heart Association, the estimated annual incidence of myocardial infarction (MI) is 600,000 new attacks and 320,000 recurrent attacks. Even with the best of care and successful early intervention, such as tissue plasminogen activator (tPA) or emergency angioplasty, about 30% of heart attack patients will eventually go on to develop decompensation through ventricular remodeling and progressive congestive heart failure. This explains in large part why heart failure remains an epidemic health problem despite improved treatments for acute cardiac events.

The safety of systemic IGF-I pr
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Genmab Announces Encouraging Preclinical Data for ofatumumab
2. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
3. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
4. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
5. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
6. Arpida Presents Preclinical Data on AR-2474 at ICAAC
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
9. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
10. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
11. GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)...ALTHAM, Mass., Oct. 13 /- Proteon The...g an important preclinical,demonstration of the po...,suffering from lower limb peripheral arterial dis...heter-Directed Elastase Therapy: A Novel,Approach ...at the 20th,annual Transcatheter Cardiovascular Th...
(Date:10/13/2008)... Ziehm Academy - New Courses on the Practical Imp...ive Imaging, NUREMBERG, Germany, October 13 /PRNe...wide Ziehm Academy Education Program at the beginn... x-ray based imaging systems, is,consequently expa...es,training in line with international standards, ...
(Date:10/13/2008)...A confirms appropriateness of durable pain palliat...uct marketing approval, Milestone achievemen...WA and VANCOUVER, Oct. 13 /...oday announced that it concluded a,meeting with th...er 7,2008, and that the FDA agreed that "durable ...
(Date:10/12/2008)...EATTLE, Oct. 13 /- Cell The...een selected to present at three upcoming,investor...al BIO Investor,Forum in San Francisco in October,...erence, and the 9th Annual Acumen BioFin Rodman & ... New York City., The presentations will be webcas...
Breaking Biology Technology:Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008 2Ziehm Imaging Extends its Training Offer 2Ziehm Imaging Extends its Training Offer 3Ziehm Imaging Extends its Training Offer 4OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011 2OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011 3OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011 4Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences 2
...ng" and "fishing" have taken on new meaning, and t...ing of your personal and business identity. , ,Eve...ith official looking e-mails sent by con artists m...ank. , Listen in on the WTN Radio report on bra...on company that recently rooted out tsunami-relate...
...z. Technology industry insiders flocked to the D...e most innovative technologies that have been intr... at this confab, which celebrated its 15th anniver...an 250 million readers, listeners and viewers worl...lens through which we can look at the state of the...
... of six states to receive a $50,000 grant to pull ... network further into the Internet age. , ,Wiscons...e state,s Office of Justice Assistance, which hous...JIS) program. WIJIS is charged with maintaining, p...ation systems. , ,WIJIS is developing solutions to...
...n your community when power stands still? , ,A. T...in to wag; its always someone elses fault. , ,C. ...eir own initiative. , ,If you answered "C," you m...t year for the first time in our companys seven ye...ed us. Unwilling to wait for their communitys trad...
Other Biology Technology:Phishing and pharming: Is your personal identity being harvested? 2Phishing and pharming: Is your personal identity being harvested? 3In search of the next big thing at DEMO 2In search of the next big thing at DEMO 3State receives grant for justice information sharing 2Lead, follow or get out of the way 2
(Date:10/10/2008)...available in German . , DNA, the molecule tha...l forms of life, is highly resistant against alter...mechanism for its photostability presents some puz...tween the four chemical bases that make up the DNA...ceeded in showing that DNA strands differ in their...
(Date:10/9/2008)...lif., Oct. 9 /PRNewswire-FirstCall/ -- Synaptics(R...er of human interface,solutions for mobile computi...ounced today that it will report financial results... October 23, 2008 after the close of market. The,c...or analysts and,investors at 2:00 p.m. PT (5:00 p....
(Date:10/9/2008)...ange exceed life,s ability to respond? Biodiversit...8 issue of the journal, Science , illustrates tha...hsonian Tropical Research Institute in Panama clea... diverse region of rainforest and coral reefs, the...global warming. Some disagree, arguing that tropic...
(Date:10/9/2008)...nty-five years, the number of patients with compro...h-risk patients such as these require a unique set...ion everything from the etiology and degree of imm...ional status. A new text from ASM Press, Diagnosti...mines a wide range of approaches and challenges to...
Breaking Biology News(10 mins):Can genetic information be controlled by light? 2Synaptics to Report First Quarter Results on October 23 2Smithsonian perspective: Biodiversity in a warmer world 2Text focuses on diagnosing infections in immunocompromised patients 2Adults With ADHD Lose 3 Weeks Worth of Work Annually 20330 1Adults With ADHD Lose 3 Weeks Worth of Work Annually 20330 2Adults With ADHD Lose 3 Weeks Worth of Work Annually 20330 3CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions 5643 1CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions 5643 2Cancer Patients Should Steer Clear of Antioxidants 20323 1Cancer Patients Should Steer Clear of Antioxidants 20323 2Cancer Patients Should Steer Clear of Antioxidants 20323 3Cornell receives federal grants to create fabrics to render toxic chemicals harmless 20319 1Cornell receives federal grants to create fabrics to render toxic chemicals harmless 20319 2
...e of fat, suggests a new study published in the Ma... from the diet or generated from sugars spark a ca...healthy blood levels of sugar, cholesterol, and ot...stores alone failed to set those critical metaboli...mice suggest that normal metabolism requires so-ca...
... repairing lung damage, according to a team of sci...rences to analyze the repair process in lung trans...the journal Transplantation, lead author Dani Zand...l at Houston, and colleagues at the University of ... percent of a certain type of reparative lung stem...
...itical to the structure and function of cells and ...ir growing ends constantly elongate and retreat in...rization, like the writhing snakes of Medusa,s hai...s ongoing rapid growth and shrinkage is key to the...or the first time, researchers have revealed at mo...
...iseases (STDs) requires treatment of the sexual pa...t providing infected men with antibiotics to give ...means of contacting and treating the partners, acc...cal Infectious Diseases, now available online. Men...ee and talk to their female partners about the STD...
Other Biology News:Fat's fate depends on its source 2Candida albicans Genome Fully Annotated 2Candida albicans Genome Fully Annotated 3The making and breaking of microtubules 2The making and breaking of microtubules 3The making and breaking of microtubules 4The making and breaking of microtubules 5New Finding May Aid Adult Stem Cell Collection 2New Finding May Aid Adult Stem Cell Collection 3
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w).
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L.
Request Info
Bsg I from New England Biolabs
Biology Products: